Drug intelligence / Profile preview

EV029104

Development stage: Preclinical
Lead developer: Absolute Antibody
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

EV029104 is a fully human IgG1 monoclonal antibody developed by Evec for the treatment and prevention of *Clostridium difficile* infection (CDI). The antibody specifically targets and neutralizes *Clostridium difficile* toxin B (TcdB), one of the primary virulence factors responsible for the symptoms and pathology of CDI, including diarrhea and pseudomembranous colitis. By binding to TcdB, EV029104 prevents the toxin from entering host cells and causing cytotoxic effects. As of the latest reports, the drug is in the preclinical stage of development.

Targets

TcdB (Clostridioides difficile toxin B)

Beyond the preview

Go deeper on EV029104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EV029104.

Explore the full profile